A genetic view of laryngeal cancer heterogeneity
| Autor: | Amancio Carnero, María José de Miguel-Luken, Manuel Chaves-Conde |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Molecular biology larynx/laryngeal cancer medicine.medical_treatment larynx preservation Improved survival laryngeal cancer treatment Review Biology Models Biological Genetic Heterogeneity 03 medical and health sciences 0302 clinical medicine Larynx preservation medicine Animals Humans Genetic Predisposition to Disease Intensive care medicine Laryngeal Neoplasms Molecular Biology Modalities Gold standard Cancer Cell Biology DNA Damage Repair medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Cytogenetic Analysis biomarker Smoking cessation Biomarker (medicine) Signal Transduction Developmental Biology |
| Zdroj: | Cell Cycle. 15:1202-1212 |
| ISSN: | 1551-4005 1538-4101 |
| DOI: | 10.1080/15384101.2016.1156275 |
| Popis: | During the recent decades significant improvements in the understanding of laryngeal molecular biology allowed a better characterization of the tumor. However, despite increased molecular knowledge and clinical efforts, survival of patients with laryngeal cancer remains the same as 30 years ago. Although this result may not make major conclusions as preservation approaches were not broadly used until the time of database collection, it seems to be clear that there is still window for improvement. Although the cornerstone for laryngeal cancer eradication is to implement smoking cessation programs, survival progresses will be hopefully seen in the future. Introducing molecular biomarkers as predictive factors to determine which patients will benefit of preservation treatments may become one of the next steps to improve survival. Furthermore, the development of new therapeutic modalities joint to biomarkers to selectively apply such new therapy in these patients may help to define new modalities with improved survival. New inhibitors against Notch pathway, EGFR, VRK1 or DNA damage repair may become gold standard if we are able to identify patients that may benefit from them, either on survival or functional larynx preservation. It is the moment for an inflexion point on the way laryngeal cancer is clinically managed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|